Privatdozent Dr. med. Brandt-Jürgens
Fachlich auf dem neuesten wissenschaftlichen Stand!
Sie und Ihre Gesundheit stehen im Mittelpunkt unserer leistungsstarken Praxis.
Wir nehmen uns Zeit, individuell auf Ihre Wünsche und Vorstellungen einzugehen.
Privatdozent Dr. med. Brandt-Jürgens betreibt seit über 20 Jahren hochschulmedizinisch geprägte Rheumatologie.
Er hält regelmäßig Vorlesungen im Fach Rheumatologie an der Charité.
Durch seine langjährige wissenschaftliche Tätigkeit und Mitgliedschaft in der internationalen Forschergruppe ASAS (Assessment in Spondyloarthritis international Society) verfügt er über umfassende Kenntnisse zu neuesten Therapiemöglichkeiten.
So werden die Patienten in seinem Team auf höchstem Niveau behandelt.
Wir bieten zusätzlich an, Sie mit innovativen Medikamenten im Rahmen von wissenschaftlichen Studien zu behandeln.
Aktuell können Sie an Therapiestudien teilnehmen zu:
- Morbus Bechterew (Spondyloarthritis)
- Psoriasis-Arthritis und
- rheumatoide Arthritis
Der berufliche Werdegang von PD Dr. med. Brandt-Jürgens im Überblick:
Studium
Humanmedizin an der Freien Universität Berlin
Dissertation
Untersuchungen über Yersinien, Chlamydien und Borrelien als Auslöser von reaktiver Arthritis.
Prof. Dr. R. Gotzen, FU-Berlin
Habilitation
Lehrbefugnis mit Lehrtätigkeit im Fach Innere Medizin an der Charité,
Universitätsmedizin Berlin
Berufliche Tätigkeiten
- Abt. f. allg. Innere Medizin und Nephrologie, Leiter: Prof. Dr. A. Distler,
Klinikum Benjamin Franklin, FU-Berlin - Abt. f. Gastroenterologie, Infektiologie und Rheumatologie, Leiter: Prof. Dr. M. Zeitz, Klinikum Benjamin Franklin, FU-Berlin
- klinische und wissenschaftliche Tätigkeit in der Abt. f. Rheumatologie, Leiter: Prof. Dr. J. Sieper,
Klinikum Benjamin Franklin, FU-Berlin - Oberarzt: Rheumaklinik Bad Bramstedt, Rheumatologie,
Universität Lübeck, Leiter: Prof. Dr. W. L. Gross - Oberarzt: Rheumazentrum Ruhrgebiet, Herne, Leiter: Prof. Dr. J. Braun
- ASAS membership; Assessment in Ankylosing Spondylitis International Working Group
Preise
- Forschungspreis 1999, 1. Platz des Fachbereiches Humanmedizin des Universitätsklinikums Benjamin Franklin.
Brandt J, Haibel H, Sieper J, Braun J. Successful anti-TNFα treatment in ankylosing spondylitis – a pilot study - Forschungspreis 2002, 1. Platz des Fachbereiches Humanmedizin des Universitätsklinikums Benjamin Franklin.
Brandt J, Haibel H, Rudwaleit M,Sieper J, Braun J. TNFα-Blockade mit Infliximab und Etanercept bei aktiver ankylosierender Spondylitis
Wichtigste Publikationen
- Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2020 Feb;79(2):193-201. doi: 10.1136/annrheumdis-2019-216034. Epub 2019 Oct 11. PMID: 31604704; PMCID: PMC7025729.
- Kiltz U, Sfikakis P, Gaffney K, Sator P, Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain P, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study. Adv Ther (2020). https://doi.org/10.1007/s12325-020-01352-8
- P Wiland, S Jeka, E Dokoupilová, Jan Brandt-Jürgens, J Limón, M Moreira, R Cabello, J Jauch-Lembach, Anjali Thakur, H Haliduola, I Brueckmann, N Gaylis. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. Biodrugs. 2020. doi: 10.1007/s40259-020-00447-6
- E Riechers, N Baerlecken, X Baraliakos, K Bakhsh, P Aries, B Bannert, K Becker, J Brandt-Jürgens, J Braun, B Ehrenstein, H Euler, M Fleck, R Hein, K Karberg, L Köhler, T Matthias, R Max, A Melzer, D Meyer-Olson, J Rech, K Rockwitz, M Rudwaleit, R Schmidt, E Schweikhard, J Sieper, C Stille, U von Hinüber, P Wagener, H Weidemann, S Zinke, T Witte.Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis Arthritis Rheumatol. 2019 May;71(5):729-735.
- Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J. Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Ann Rheum Dis. 2019 Oct 11.
- Heldmann F, Baraliakos X, Kiltz U, Brandt J, van der Horst-Bruinsma IE, Landewé R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Gaston H, Gruenke M, Witt M, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Braun J; Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):184-90.
- Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Ann Rheum Dis. 2016 Feb 10.
- Baraliakos X, Heldmann F, Callhoff J, Listing J, Appelboom T, Brandt J, Van den Bosch F, Breban M, Burmester G, Dougados M, Emery P, Gaston H1, Grunke M, Van Der Horst-Bruinsma IE, Landewé R, Leirisalo-Repo M, Sieper J, De Vlam K, Pappas D, Kiltz U, Van Der Heijde D, Braun J.
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014 Oct;73(10):1819-25. - Brandt J.;
Leflunomide and TNF inhibitors. Experiences from precription recourse proceedings. Z Rheumatol. 2013 Mar;72(2):114-6. - Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, van den Bosch F, de Vlam K, Geusens P, Gaston H, Schewe S, Appelboom T, Emery P, Dougados M, Leirisalo-Repo M, Breban M, Listing J, Braun J.
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2011 Jul-Aug;29(4):672-80. - Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y, Van den Bosch F, Olivieri I, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Weber U, Wei J, Sieper J.
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan;70(1):25-31. - Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W, van der Heijde D.
- The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009 Jun;68 Suppl 2:ii1-44.
- Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009 Jun;68(6):770-6. - Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83. - Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Rudwaleit M.
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS).
Ann Rheum Dis. 2009 Jun;68(6):784-8. - Gladman DD, Inman RD, Cook RJ, van der Heijde D, Landewé RB, Braun J, Davis JC, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O’Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, Maksymowych WP.
International spondyloarthritis interobserver reliability exercise–the INSPIRE study: I. Assessment of spinal measures. J Rheumatol. 2007 Aug;34(8):1733-9. - Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, Landewé RB, Mease P, Brandt J, Vargas RB, Chandran V, Helliwell P, Kavanaugh A, O’Shea FD, Khan MA, Pipitone N, Rahman P, Reveille JD, Stone MA, Taylor W, Veale DJ, van der Heijde D.
International spondyloarthritis interobserver reliability exercise–the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007 Aug;34(8):1740-5. - Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J.
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford). 2007 Sep;46(9):1450-3. - Kiltz U, Brandt J, Zochling J, Braun J.
Rheumatic manifestations of lymphoproliferative disorders. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):35-9 - Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007 Jul;66(7):910-5.
- Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, Sörensen H, Zeidler H, Visvanathan S, Sieper J, Braun J.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007 Mar;34(3):510-5. - Brandt J, Marzo-Ortega H, Emery P.
Ankylosing spondylitis: new treatment modalities. Best Pract Res Clin Rheumatol. 2006 Jun;20(3):559-70. - Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gömör B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J.
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006 Sep;65(9):1147-53. - Alberding A, Stierle H, Brandt J, Braun J.
Effectiveness and safety of radium chloride in the treatment of ankylosing spondylitis. Results of an observational study]. Z Rheumatol. 2006 May;65(3):245-51. - Brandt J, Braun J.
Anti-TNF-alpha agents in the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2006 Feb;6(2):99-107. - Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis. 2006 Feb;65(2):201-8 - Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum. 2005 Dec 15;53(6):856-63. - Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol. 2005 May-Jun;34(3):178-90.
- Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Braun J. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford). 2005 Dec;44(12):1525-30.
- Zochling J, Brandt J, Braun J.
The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford). 2005 Dec;44(12):1483-91. - Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J.
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis. 2005 Sep;64(9):1305-10. - Metzler C, Arlt AC, Gross WL, Brandt J.
Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide.
Ann Rheum Dis. 2005;64:1798-800. - Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
Successful Short Term Treatment of Patients with Severe Undifferentiated Spondyloarthritis with the Anti-Tumor Necrosis Factor α Fusion Receptor Protein Etanercept. J Rheumatol. 2004;31:531-8. - Brandt J, Listing J, Sieper J, Rudwaleit M, Van Der Heijde D, Braun J.
Development and preselection of criteria for short-term improvement after anti-TNFα therapy in ankylosing spondylitis.
Ann Rheum Dis. 2004 Nov;63(11):1438-44. Epub 2004 Mar 25. - Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester, G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J.
Long-Term Efficacy and Safety of Infliximab in the Treatment of Ankylosing Spondylitis. Arthritis Rheum 2003;48:2224-33. - Braun J*, Brandt J*, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H,Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J.
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-93.
*beide Autoren sind gleichwertige Erstautoren - Brandt J, Haibel H, Reddig J, Sieper J, Braun J.
Treatment of patients with severeankylosing spondylitis with infliximab – a one year follow up. Arthritis Rheum 2001;44:2936-37. - Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J,Braun J.
Successful treatment of actice ankylosing spondylitis with the anti-tumornecrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum 2000;43:1346-52. - Brandt J, Bollow M, Häberle J, Rudwaleit M, Eggens U, Distler A, Sieper J, Braun J.
Studying patients with inflammatory back pain and arthritis of the lower limbs clinicallyand by magnetic resonance imaging –
many, but not all patients with sacroiliitis have spondyloarthropathy. - Rheumatology 1999;38:831-36.
Brandt J, Rudwaleit M, Eggens U, Mertz A, Distler A, Sieper J, Braun J.
Increased Frequency of Sjögren´s syndrome in patients with spondylarthropathy. J Rheumatol 1998;25:718-24.